Rasagiline

NIOSH table

Table 2 Non-antineoplastic — eligible for a documented Assessment of Risk.

AHFS classification

28:36 antiparkinsonian agents; 28:16.04.12 monoamine oxidase inhibitors

This page reports this drug’s status on the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. It is not a hazard determination and not a handling instruction. Your facility makes its own Assessment of Risk under USP <800>. Package-insert content changes when the manufacturer revises the label — always screen the current insert before relying on it.